|
|
Article: New Study Reinforces Safety and Clinical Efficacy of ALK-Abello's Tablet Against Grass Pollen Allergy.
- Article from:
- PR Newswire Europe
- Article date:
- January 6, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
COPENHAGEN, Denmark, January 6 /PRNewswire/ -- According to preliminary results from a new study (GT-07) announced today, ALK-Abello's ground-breaking tablet-based allergy immunotherapy treatment reduces rhino-conjunctivitis (hay fever) symptoms by 37%, whilst reducing the need for symptom relieving medication by 41% (compared with placebo).
The GT-07 study demonstrates the efficacy and confirms the favourable safety profile of the grass tablet, recently reported in the phase IIb/III trial (GT-02) - the largest allergy immunotherapy study ever performed[1].
"These are exciting results for ALK-Abello," commented Jens Bager, CEO, ALK-Abello A/S. "This ...